Pfizer, Inc.
Recent
price
P/E
ratio
div
yld
5.61%
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Pfizer Inc. (NYSE: PFE) develops, manufactures, and markets biopharmaceutical products worldwide, focusing on oncology, vaccines, internal medicine, inflammation and immunology, and rare diseases. The company offers a broad portfolio including oncology drugs such as Ibrance (palbociclib), Xtandi (enzalutamide), Padcev (enfortumab vedotin), Elrexfio (elranatamab), Bosulif (bosutinib), Braftovi (encorafenib), Lorbrena (lorlatinib), Talzenna (talazoparib), and Tivdak (tisotumab vedotin); vaccines like Comirnaty (COVID-19 mRNA vaccine), Prevnar 13/20 (pneumococcal conjugate vaccines), Abrysvo (RSV vaccine), and Penbraya (meningococcal vaccine); cardiovascular and metabolic treatments including Eliquis (apixaban), Vyndaqel/Vyndamax (tafamidis), and Norvasc (amlodipine); primary care products such as Zavzpret (zavegepant), Chantix (varenicline), and Litfulo (ritlecitinib); antivirals like Paxlovid (nirmatrelvir/ritonavir); and consumer brands including Advil, ChapStick, and Robitussin. Founded in 1849 by Charles Pfizer and Charles F. Erhart and headquartered at 235 East 42nd Street in Manhattan, New York City, Pfizer operates manufacturing and research facilities globally across North America, Europe, Asia, and Latin America, serving healthcare providers, governments, and patients in over 100 countries. In recent developments, Pfizer completed the acquisition of Metsera in November 2025 for an initial enterprise value of $4.9 billion plus a contingent value right, adding clinical-stage obesity and cardiometabolic candidates including oral and injectable incretins; new products and acquired launches contributed $7.3 billion in incremental revenue through Q3 2025; and the company plans $10-15 billion in business development investments for 2025, emphasizing early-stage assets and collaborations, particularly with Chinese biotechs via its Ignite platform.
Company News
Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip
Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb?
What Higher Interest Rates Mean for Dividend Stocks Like AbbVie and Pfizer
Bristol Myers Squibb vs. Pfizer: Consistency vs.
Moderna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher
Pfizer's High Dividend Yield May Be a Warning. Here's How Merck Compares
Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing
Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Inches Higher
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Pfizer's Stock Is Finally Showing Signs of Life. Could This Be the Start of a Much Bigger Rally?
5 Dividend Stocks for Investors Who Want Income Without the Market's Wild Swings
Pfizer's Non-Oncology Performance in Q3: Driving Factors to Watch
Pfizer's Dividend Freeze Raises a Bigger Question About Its Cash Flow
These 5 Dividend Stocks Look Like Income Bargains. The Math Says Otherwise
$50,000 in These 5 Dividend Stocks Could Pay You $2,700 a Year
Warren Buffett's Market Warning Is Hard to Ignore. But I'd Buy These 3 Stocks Anyway.
Here's What $10,000 in Each of These 5 High-Yield Dividend Stocks Could Pay You in a Year
Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe?
Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady
Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put